Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450851 · ClinicalTrials.gov registry record
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
A clinical trial of Genetic Disease, sponsored by National Human Genome Research Institute (NHGRI).
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 20
- Study locations
NCT02450851: Recruiting study of Genetic Disease, sponsored by National Human Genome Research Institute (NHGRI).
NCT02450851 is a study of Genetic Disease that is actively recruiting participants, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 20,000 participants, above the 1,895-participant average among 30 other Genetic Disease trials with a reported enrollment target (955% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02450851, a study of Genetic Disease, is actively recruiting participants, sponsored by National Human Genome Research Institute (NHGRI).
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC) (1-3). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible. To date, the UDP has evaluated 3300 medical records and admitted 750 individuals with rare and undiagnosed conditions to the NIH Clinical Center. The NIH UDP has identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the Undiagnosed Diseases Network (UDN), for fiscal years 2013-2020. The clinical sites will perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood
Primary Outcome
Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic process on patients and families, and share this understanding to identify improved options for optimal patient management.
Conditions Studied
Study Locations (20)
California
- University of California, Los Angeles - Los Angeles
- University of California, Irvine Medical Center - Orange
- Lucile Salter Packard Children's Hospital at Stanford - Stanford
- Stanford University - Stanford
- Leland Stanford Junior University - Stanford
- Stanford Hospital and Clinics - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children s Hospital - Boston
- Brigham and Women's Hospital - Boston
- Harvard T.H. Chan School of Public Health - Boston
- Harvard U Faculty of Medicine - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
- HudsonAlpha Institute for Biotechnology, Inc. - Huntsville
District of Columbia
- Childrens National Medical Center - Washington D.C.
Florida
- University of Miami Miller School of Medicine - Miami
Illinois
- Lurie Children s Hospital - Chicago
Indiana
- Indiana University - Indianapolis
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2015-09-16 |
| Est. Completion | 2028-12-31 |
What NCT02450851 shows while recruiting
NCT02450851 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,895-participant average among 30 other Genetic Disease trials with a reported enrollment target (955% higher).
The record links to 1 condition, with Genetic Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02450851 names 20 study sites across 10 states, led by California, Massachusetts, Alabama.
Frequently Asked Questions
What is clinical trial NCT02450851 about?
NCT02450851 is a clinical study titled "Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network". Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insigh...
What is the current status of trial NCT02450851?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2015-09-16. Estimated completion is 2028-12-31.
What conditions does trial NCT02450851 study?
This clinical trial studies the following conditions: Genetic Disease.
Who is sponsoring clinical trial NCT02450851?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02450851 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02450851's enrollment target sits among peer trials
20,000 2nd of 30 the highest of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Follow-up With Preimplantation Genetic Testing Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI